

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re patent application of

Patrick BENOIT *et al.*

Serial No. 09/240,675

Filed: February 2, 1999

For: MONOCLONAL ANTIBODIES AGAINST THE INTERFERON RECEPTOR  
WITH NEUTRALIZING ACTIVITY AGAINST TYPE I INTERFERON



Group Art Unit: 1645

Examiner: S. Devi

JAN 11 2001

TECH CENTER 1600/2900

AMENDMENT AND REQUEST FOR RECONSIDERATION  
UNDER 37 C.F.R §1.116

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This communication is responsive to the Office Action mailed in the above-captioned case on September 8, 2000.

Petition is hereby made for a one month extension of time up to and including January 8, 2001. A check is attached in full payment of all fees believed to be due in connection with submission of this paper. If the amount is incorrect, however, the Commissioner is authorized to make appropriate charges or credits to Deposit Account No. 19-0741 to provide exact payment.

Reconsideration and reexamination of the application in light of the amendments and remarks herein set forth is respectfully requested.

IN THE CLAIMS:

Please amend the claims as follows:

Claim 23. (Thrice Amended) An isolated peptide or polypeptide which is a fragment of the extracellular portion of the interferon receptor (IFN-R) of SEQ ID NO: 1<sup>2</sup> or 2<sup>A</sup>, said peptide or polypeptide consisting of an amino acid sequence from position 27 to position 427 of SEQ ID NO: 1<sup>2</sup> or 2<sup>A</sup> or a portion thereof; wherein said peptide or polypeptide or a portion thereof specifically binds to monoclonal antibody 64G12 deposited at the ECACC under no. 92022605.

12/E  
A.Q.  
1/19/01  
(NE)

O.K. to  
enter  
as

2/1/01  
E